Figure 1.

A, Event Free Survival of CLL patients who started therapy with standard dose ibrutinib (420 mg daily) compared to reduced dose ibrutinib (<420 mg daily) B, Overall Survival of CLL patients who started therapy with standard dose ibrutinib (420 mg daily) compared to reduced dose ibrutinib (<420 mg daily)